130 related articles for article (PubMed ID: 12749725)
41. Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
Yanagisawa Y; Maruta F; Iinuma N; Ishizone S; Koide N; Nakayama J; Miyagawa S
Scand J Gastroenterol; 2007 Apr; 42(4):477-84. PubMed ID: 17454858
[TBL] [Abstract][Full Text] [Related]
42. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis.
Shahnam A; Ridha Z; Wiese MD; Kichenadasse G; Sorich MJ
Pharmacogenomics; 2016 Oct; 17(15):1725-1732. PubMed ID: 27636246
[TBL] [Abstract][Full Text] [Related]
43. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
44. Pharmacogenomics and colorectal cancer.
Lenz HJ
Adv Exp Med Biol; 2006; 587():211-31. PubMed ID: 17163168
[TBL] [Abstract][Full Text] [Related]
45. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.
Cortejoso L; García MI; García-Alfonso P; González-Haba E; Escolar F; Sanjurjo M; López-Fernández LA
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1463-72. PubMed ID: 23543295
[TBL] [Abstract][Full Text] [Related]
46. [New perspectives in predicting response to chemotherapy in colorectal cancer].
Sempere L; Jover R
Gastroenterol Hepatol; 2008 Nov; 31(9):580-6. PubMed ID: 19091247
[TBL] [Abstract][Full Text] [Related]
47. Factors predicting the response to oral fluoropyrimidine drugs: a phase II trial on the individualization of postoperative adjuvant chemotherapy using oral fluorinated pyrimidines in stage III colorectal cancer treated by curative resection (ACT-01 Study).
Mori T; Ohue M; Takii Y; Hashizume T; Kato T; Kotake K; Sato T; Tango T
Oncol Rep; 2013 Feb; 29(2):437-44. PubMed ID: 23232805
[TBL] [Abstract][Full Text] [Related]
48. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies.
Qian YY; Liu XY; Wu Q; Song X; Chen XF; Liu YQ; Pei D; Shen LZ; Shu YQ
Asian Pac J Cancer Prev; 2014; 15(19):8383-90. PubMed ID: 25339033
[TBL] [Abstract][Full Text] [Related]
49. Microsatellite instability in the management of stage II colorectal patients.
Strâmbu V; Garofil D; Pop F; Radu P; Brătucu M; Iorga C; Iorga R; Pasnicu C; Ion A; Popa F
Chirurgia (Bucur); 2013; 108(6):816-21. PubMed ID: 24331320
[TBL] [Abstract][Full Text] [Related]
50. Role of microsatellite instability in the management of colorectal cancers.
Buecher B; Cacheux W; Rouleau E; Dieumegard B; Mitry E; Lièvre A
Dig Liver Dis; 2013 Jun; 45(6):441-9. PubMed ID: 23195666
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
Yamada H; Iinuma H; Watanabe T
Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
[TBL] [Abstract][Full Text] [Related]
52. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
Schmoll HJ
Semin Oncol; 2002 Oct; 29(5 Suppl 15):34-9. PubMed ID: 12422306
[TBL] [Abstract][Full Text] [Related]
53. Pharmacogenetics of stomach cancer.
Toffoli G; Cecchin E
Suppl Tumori; 2003; 2(5):S19-22. PubMed ID: 12914384
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer.
Jensen SA; Vainer B; Witton CJ; Jørgensen JT; Sørensen JB
Acta Oncol; 2008; 47(6):1054-61. PubMed ID: 18607850
[TBL] [Abstract][Full Text] [Related]
55. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Koumarianou A; Tzeveleki I; Mekras D; Eleftheraki AG; Bobos M; Wirtz R; Fountzilas E; Valavanis C; Xanthakis I; Kalogeras KT; Basdanis G; Pentheroudakis G; Kotoula V; Fountzilas G
Anticancer Res; 2014 Sep; 34(9):4949-62. PubMed ID: 25202077
[TBL] [Abstract][Full Text] [Related]
56. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Nöpel-Dünnebacke S; Schulmann K; Reinacher-Schick A; Porschen R; Schmiegel W; Tannapfel A; Graeven U
Z Gastroenterol; 2014 Dec; 52(12):1394-401. PubMed ID: 25474278
[TBL] [Abstract][Full Text] [Related]
58. Correlations between expression levels of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase, and efficacy of 5-fluorouracil-based chemotherapy for advanced colorectal cancer.
Bai W; Wu Y; Zhang P; Xi Y
Int J Clin Exp Pathol; 2015; 8(10):12333-45. PubMed ID: 26722420
[TBL] [Abstract][Full Text] [Related]
59. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C
Anticancer Res; 2011 Jan; 31(1):359-66. PubMed ID: 21273624
[TBL] [Abstract][Full Text] [Related]
60. What is the role and impact of molecular markers on treatment decisions for colorectal cancer in the adjuvant setting?
Al-Salama HM; Johnstone EC; Kerr DJ
Discov Med; 2009 Oct; 8(42):104-7. PubMed ID: 19833054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
